Literature DB >> 18496560

Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.

U Modlich1, A Schambach, M H Brugman, D C Wicke, S Knoess, Z Li, T Maetzig, C Rudolph, B Schlegelberger, C Baum.   

Abstract

Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common gamma-chain (IL2RG), the coding sequence required for correction of X-linked severe combined immunodeficiency. Similar to conventional gamma-retroviral vectors, self-inactivating (SIN) vectors with strong internal enhancers also triggered profound clonal imbalance, yet with a characteristic insertion preference for a window located downstream of the transcriptional start site. Controls including lentivirally transduced cells revealed that ectopic IL2RG expression was not sufficient to trigger leukemia. After serial bone marrow transplantation involving 106 C57Bl6/J mice monitored for up to 18 months, we observed leukemic progression of six distinct clones harboring gamma-retroviral long terminal repeat (LTR) or SIN vector insertions in Evi1 or Prdm16, two functionally related genes. Three leukemic clones had single vector integrations, and identical clones manifested with a remarkably similar latency and phenotype in independent recipients. We conclude that upregulation of Evi1 or Prdm16 was sufficient to initiate a leukemogenic cascade with consistent intrinsic dynamics. Our study also shows that insertional mutagenesis is required for leukemia induction by IL2RG vectors, a risk to be addressed by improved vector design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496560     DOI: 10.1038/leu.2008.118

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

1.  Assessing the risk of T-cell malignancies in mouse models of SCID-X1.

Authors:  Brian Sorrentino
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

2.  Preventing and exploiting the oncogenic potential of integrating gene vectors.

Authors:  Ute Modlich; Christopher Baum
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

Review 3.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

Review 4.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

5.  Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.

Authors:  Olga S Kustikova; Bernhard Schiedlmeier; Martijn H Brugman; Maike Stahlhut; Stefan Bartels; Zhixiong Li; Christopher Baum
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

6.  Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.

Authors:  Paritha I Arumugam; Tomoyasu Higashimoto; Fabrizia Urbinati; Ute Modlich; Shawna Nestheide; Ping Xia; Catherine Fox; Andrea Corsinotti; Christopher Baum; Punam Malik
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

7.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.

Authors:  Ute Modlich; Susana Navarro; Daniela Zychlinski; Tobias Maetzig; Sabine Knoess; Martijn H Brugman; Axel Schambach; Sabine Charrier; Anne Galy; Adrian J Thrasher; Juan Bueren; Christopher Baum
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

8.  Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia.

Authors:  Dirk Heckl; Adrian Schwarzer; Reinhard Haemmerle; Doris Steinemann; Cornelia Rudolph; Britta Skawran; Sabine Knoess; Johanna Krause; Zhixiong Li; Brigitte Schlegelberger; Christopher Baum; Ute Modlich
Journal:  Mol Ther       Date:  2012-04-03       Impact factor: 11.454

9.  Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

10.  Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.

Authors:  M A Sadat; S Dirscherl; L Sastry; J Dantzer; N Pech; S Griffin; T Hawkins; Y Zhao; C N Barese; S Cross; A Orazi; C An; W S Goebel; M C Yoder; X Li; M Grez; K Cornetta; S D Mooney; M C Dinauer
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.